Anson Funds Management’s NextCure NXTC Stock Holding History

Anson Funds Management’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,611	Closed	-$692K	–	405
2021 Q4	$692K	Buy	+9,611	New	+$804K	0.07%	209

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Anson Funds Management's NXTC Position: Q1 2022 in Review

Anson Funds Management sold out of NextCure (NXTC) in Q1 2022, closing a stake of 9,611 shares — an estimated $692K sold.

Anson Funds Management first reported a position in NXTC in Q4 2021 and held it in 1 quarter. The position peaked at $692K in Q4 2021. 59 funds tracked by Wall St. Rank hold NXTC as of Q1 2022.

Anson Funds Management reported no remaining NextCure position as of Q1 2022 after selling out during the quarter.
Anson Funds Management sold 9,611 NextCure shares in Q1 2022, an estimated $692K.
Anson Funds Management first reported a position in NextCure in Q4 2021 and held it in 1 quarter.
Anson Funds Management's NextCure position peaked at $692K in Q4 2021.
59 funds tracked by Wall St. Rank held NextCure as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.